ArticleMedicine2026
Associations of novel adiposity indices with gynecological cancer risk among adult women: Evidence from NHANES 2011 to 2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central adiposity is a major metabolic risk factor, but its relationship with gynecological cancers (GCs) remains incompletely understood. This study investigated the associations of Body Roundness Index (BRI) and A Body Shape Index (ABSI) with gynecological cancers among U.S. women. Data from 8116 women aged ≥ 20 years in the National Health and Nutrition Examination Survey 2011 to 2018 were analyzed. BRI and ABSI were derived from standardized anthropometric measurements. GC status was based on self-reported physician diagnosis of cervical, endometrial, or ovarian cancer. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for covariates. Women with GC (n = 194) had significantly higher mean BRI and ABSI values than non-GC participants. Each one-unit increase in BRI was associated with a 14% higher odds of GC (OR = 1.14, 95% CI: 1.03-1.31, P = .019). Compared to the lowest quartile, women in the highest BRI quartile had 1.71-fold greater odds of GC (95% CI: 1.11-2.62). For ABSI, women in the top quartile had 1.53-fold higher odds (95% CI: 1.01-2.32). Associations were strongest among overweight women and those not using female hormones. Higher BRI and ABSI, reflecting central adiposity, were independently associated with increased odds of gynecological cancer in U.S. women. These indices may serve as practical markers for identifying women at elevated cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.